Baccine

Company Overview

Snapshot

Founded in February 2022 by Guy Neev, Baccine operates with 1–10 employees. The company has secured funding across three rounds from two investors, including Terra Venture Partners. Baccine is a pre-clinical biotechnology company developing bacteria-based cancer vaccines.

Business overview

Baccine is a pre-clinical biotechnology company focused on developing innovative proprietary bacteria-based cancer vaccines. The company's multi-acting approach aims to provide efficient immunotherapy treatments with increased response rates and reduced side effects through localized action. Baccine was established in collaboration with the Weizmann Institute of Science, leveraging extensive research into cancer resistance mechanisms, the tumor microenvironment, and the role of bacteria in tumors. It operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology, targeting patients in the healthcare and life sciences markets.

Company Intelligence Q&A

What is Baccine's core focus?

Baccine is a pre-clinical biotechnology company developing innovative proprietary bacteria-based cancer vaccines to provide immunotherapy treatments with increased response rates and reduced side effects.

When was Baccine founded?

Baccine was founded in February 2022.

Who is a key founder of Baccine?

Guy Neev is a co-founder and CEO of Baccine.

What is the status of Baccine's product development?

Baccine's product is currently in the R&D stage, focusing on bacteria-based cancer vaccines.

Which institution did Baccine collaborate with for its establishment?

Baccine was established in collaboration with the Weizmann Institute of Science, following research into cancer resistance mechanisms and the role of bacteria in tumors.